Details of Disease

General Information of Disease (ID: DISSXRTQ)

Disease Name	T-cell lymphoma
Synonyms	T-cell non-Hodgkin lymphoma; T-cell and NK-cell non-Hodgkin lymphoma; T-cell lymphoma; T-cell non-Hodgkin's lymphoma; T-cell and NK-cell non-Hodgkin's lymphoma; T cell lymphoma; non-Hodgkin's T-cell lymphoma; T-cell NHL
Disease Class	2A90: Mature T-cell lymphoma
Definition	A non-Hodgkin lymphoma of T-cell lineage. It includes the T lymphoblastic lymphoma and the mature T- and NK-cell lymphomas. -- 2003
Disease Hierarchy	DISS2Y8A: Non-hodgkin lymphoma DISSXRTQ: T-cell lymphoma
ICD Code	ICD-11 ICD-11: 2A90 ICD-10 ICD-10: C81-C86
Disease Identifiers	MONDO ID MONDO_0015760 MESH ID D016399 UMLS CUI C0079772 MedGen ID 86957 HPO ID HP:0012190 Orphanet ID 171918 SNOMED CT ID 109978004

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Mechlorethamine	DM0CVXA	Approved	Small molecular drug	[1]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CPI-613	DM5XUQL	Phase 3	Small molecular drug	[2]
IPH4102	DMQH2SF	Phase 2	NA	[3]
CPI-818	DMMBQ20	Phase 1	Small molecular drug	[4]
CTX130	DM926CH	Phase 1	CAR T Cell Therapy	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 73 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
BCL6	TTC9YX5	Limited	Altered Expression	[6]
CR2	TT0HUN7	Limited	Biomarker	[7]
FASLG	TTO7014	Limited	Biomarker	[8]
LAG3	TTNVXAW	Limited	Altered Expression	[9]
MS4A1	TTUE541	Limited	Altered Expression	[10]
WAS	TTE8T73	Limited	Biomarker	[11]
AKT1	TTWTSCV	Disputed	Biomarker	[12]
CMA1	TT8VUE0	moderate	Biomarker	[13]
IFNGR2	TT13TL0	moderate	Genetic Variation	[14]
KCNJ6	TTTIBVP	moderate	Genetic Variation	[15]
KDM1A	TTNR0UQ	moderate	Biomarker	[16]
KDM4C	TTV8CRH	moderate	Biomarker	[16]
SLC16A1	TTN1J82	moderate	Biomarker	[13]
ASRGL1	TT4WT91	Strong	Biomarker	[17]
CCR9	TTIPS8B	Strong	Biomarker	[18]
CD37	TTFCW29	Strong	Biomarker	[19]
CD3E	TTZAT79	Strong	Biomarker	[20]
CD4	TTN2JFW	Strong	Altered Expression	[21]
CDC25C	TTESBNC	Strong	Altered Expression	[22]
CHKA	TT10AWB	Strong	Altered Expression	[23]
CRTC2	TTFWETR	Strong	Altered Expression	[24]
CXCL13	TT0NIZ1	Strong	Altered Expression	[25]
EP300	TTGH73N	Strong	Biomarker	[26]
FOXQ1	TTEJZOL	Strong	Altered Expression	[27]
FURIN	TTH9WF6	Strong	Genetic Variation	[28]
GNAQ	TTL1SRG	Strong	Genetic Variation	[29]
GZMB	TTKEPHX	Strong	Altered Expression	[30]
HDAC8	TTT6LFV	Strong	Biomarker	[31]
HSP90AB1	TTH5YN2	Strong	Biomarker	[32]
IL13RA1	TTNEAMG	Strong	Altered Expression	[33]
ITGB7	TTLT9XQ	Strong	Biomarker	[34]
ITK	TT3C80U	Strong	Biomarker	[35]
JAK3	TTT7PJU	Strong	Altered Expression	[36]
MAP3K20	TTTUZ3O	Strong	Genetic Variation	[37]
NCR1	TTQNRJM	Strong	Altered Expression	[38]
NPM1	TTHBS98	Strong	Biomarker	[39]
NUAK1	TT65FL0	Strong	Biomarker	[34]
PARP2	TTQ4V96	Strong	Biomarker	[40]
PAX5	TTA4REJ	Strong	Biomarker	[41]
PDCD1	TTNBFWK	Strong	Biomarker	[42]
PDCD2	TTYOVWN	Strong	Altered Expression	[43]
PIM1	TTTN5QW	Strong	Biomarker	[44]
PNLIP	TTXMY0J	Strong	Biomarker	[45]
PPARG	TTT2SVW	Strong	Biomarker	[46]
PRG4	TTSKF4V	Strong	Biomarker	[47]
PRKCQ	TT1MS7X	Strong	Altered Expression	[48]
REL	TT1ZCTH	Strong	Genetic Variation	[49]
RHOA	TTP2U16	Strong	Biomarker	[50]
SEPTIN6	TTAGE7U	Strong	Biomarker	[47]
STAT3	TTHJT3X	Strong	Biomarker	[51]
STK4	TTCPLVN	Strong	Genetic Variation	[52]
TCF3	TTULOD8	Strong	Genetic Variation	[53]
TCL1A	TTUKRDV	Strong	Altered Expression	[54]
TIAM1	TTNU6I5	Strong	Biomarker	[55]
TMPRSS11D	TTWHYC8	Strong	Biomarker	[56]
TNFRSF13C	TT7NJSE	Strong	Biomarker	[57]
TNFRSF17	TTZ3P4W	Strong	Genetic Variation	[58]
ABCC4	TTUEAFL	Definitive	Altered Expression	[59]
CA12	TTSYM0R	Definitive	Biomarker	[60]
CCR4	TT7HQD0	Definitive	Altered Expression	[61]
DLL1	TT9CFQD	Definitive	Biomarker	[62]
ID2	TTW8A5N	Definitive	Altered Expression	[63]
IL5	TTPREZD	Definitive	Genetic Variation	[14]
KIR3DL2	TTQH3N0	Definitive	Altered Expression	[64]
LCK	TT860QF	Definitive	Altered Expression	[65]
LONP1	TTM1VPZ	Definitive	Biomarker	[66]
MAP3K8	TTGECUM	Definitive	Biomarker	[67]
NFKB2	TTKLNRV	Definitive	Genetic Variation	[68]
NR0B2	TT25A9Q	Definitive	Biomarker	[69]
PLK2	TT976FS	Definitive	Altered Expression	[70]
PSMB6	TT8EPLT	Definitive	Biomarker	[62]
PTPN6	TT369M5	Definitive	Biomarker	[69]
ZAP70	TTUMHT8	Definitive	Altered Expression	[71]
------------------------------------------------------------------------------------


⏷ Show the Full List of 73 DTT(s)

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
ASNS	DEXISVQ	Definitive	Biomarker	[72]
------------------------------------------------------------------------------------

This Disease Is Related to 90 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CD1D	OT3ROU4J	Limited	Biomarker	[73]
GFI1B	OTRDW8YO	Limited	Biomarker	[74]
GNG8	OT9YHSF1	Limited	Genetic Variation	[75]
KRT20	OT4RB40L	Limited	Biomarker	[10]
NBN	OT73B5MD	Limited	Genetic Variation	[76]
PCDH10	OT2GIT0E	Limited	Posttranslational Modification	[77]
TSPYL2	OTGGW2EF	Limited	Genetic Variation	[78]
GNLY	OTZJKA8C	moderate	Altered Expression	[79]
MCAT	OTH07FIW	moderate	Biomarker	[13]
MCTS1	OT7SAOJP	moderate	Biomarker	[13]
S100A1	OT1F2G4J	moderate	Biomarker	[80]
STAT5B	OTZVPEBT	moderate	Altered Expression	[81]
TAL1	OTX4K6QZ	moderate	Biomarker	[82]
ACSBG1	OTM040MW	Strong	Biomarker	[83]
ADRM1	OTOU4EY6	Strong	Biomarker	[84]
AKAP13	OTOZAR14	Strong	Genetic Variation	[85]
ARID1A	OTRWDV3P	Strong	Biomarker	[26]
ASPG	OT5E2EKR	Strong	Biomarker	[86]
ASXL3	OTNDJWEZ	Strong	Biomarker	[26]
ATXN2L	OTP5M3R9	Strong	Biomarker	[87]
BCL11B	OT8KKCVJ	Strong	Biomarker	[88]
CEP55	OTGSG2PA	Strong	Altered Expression	[89]
CLDN10	OT2CVAKY	Strong	Biomarker	[90]
CLEC7A	OTRTBH27	Strong	Biomarker	[91]
CUL1	OTXPE1UZ	Strong	Biomarker	[92]
DDX3X	OTDO4TRX	Strong	Biomarker	[26]
DERL2	OTI3TUUZ	Strong	Genetic Variation	[93]
DLEC1	OTMKKBUW	Strong	Altered Expression	[94]
DLX5	OTEEFBEU	Strong	Biomarker	[95]
DLX6	OT0FIJHY	Strong	Altered Expression	[96]
ECSIT	OTJX1YC7	Strong	Genetic Variation	[97]
EMCN	OTS03CZC	Strong	Altered Expression	[98]
EPB41L3	OTS6CHG2	Strong	Posttranslational Modification	[99]
ESPL1	OTMGEVOK	Strong	Altered Expression	[100]
FBXO7	OTGTN8TJ	Strong	Altered Expression	[101]
FIP1L1	OTF91GTL	Strong	Biomarker	[102]
FRAT1	OT1PS84E	Strong	Altered Expression	[103]
GCFC2	OTC7FRXL	Strong	Altered Expression	[104]
GLIS2	OTOUUV1X	Strong	Biomarker	[105]
GTF2H4	OTPD1DIU	Strong	Genetic Variation	[68]
GZMA	OT43R33L	Strong	Biomarker	[106]
GZMM	OTEC5CWT	Strong	Altered Expression	[107]
HAVCR2	OTOL603T	Strong	Altered Expression	[9]
HPR	OTXSC9UB	Strong	Biomarker	[108]
ICAM3	OTTZ5A5D	Strong	Biomarker	[109]
ID3	OTUULW5Z	Strong	Genetic Variation	[90]
ITM2B	OTMXEPXB	Strong	Altered Expression	[6]
KDM2B	OTDMCVW7	Strong	Biomarker	[110]
KMT2D	OTTVHCLY	Strong	Biomarker	[111]
LMO4	OT5NDCT9	Strong	Altered Expression	[112]
MATK	OTVOJJLJ	Strong	Biomarker	[113]
MGA	OTTLB216	Strong	Biomarker	[26]
MRPL28	OT4LUTZU	Strong	Altered Expression	[114]
MSX1	OT5U41ZP	Strong	Biomarker	[105]
MZF1	OTMVZCPW	Strong	Biomarker	[115]
NAV3	OT97M1TR	Strong	Genetic Variation	[116]
NECTIN2	OTIE0W6O	Strong	Altered Expression	[117]
NKAIN2	OTI4H30Z	Strong	Biomarker	[118]
NOL3	OT1K0L0D	Strong	Biomarker	[119]
NXT1	OT0VO6AY	Strong	Altered Expression	[114]
PAEP	OTQA0NV4	Strong	Genetic Variation	[120]
PDLIM7	OTAZVODU	Strong	Biomarker	[121]
PHF6	OT8DXI40	Strong	Altered Expression	[122]
PIK3R5	OT4LNXJU	Strong	Altered Expression	[123]
PRC1	OTHD0XS0	Strong	Biomarker	[124]
PTPRK	OTAP5AT3	Strong	Posttranslational Modification	[125]
PWWP3A	OTXQVL4U	Strong	Biomarker	[126]
RAPH1	OTMQXW7S	Strong	Biomarker	[83]
RASGRF2	OT67DAGF	Strong	Altered Expression	[127]
RASGRP1	OTX9WN2E	Strong	Altered Expression	[128]
RECQL4	OT59LSW7	Strong	Genetic Variation	[129]
RHOJ	OTWI65OA	Strong	Genetic Variation	[130]
RPL17	OTTYMPS6	Strong	Biomarker	[131]
RRBP1	OT4ZTPTM	Strong	Biomarker	[132]
SAA2	OTYAVJWG	Strong	Biomarker	[133]
SEPTIN9	OT1VMRFQ	Strong	Biomarker	[47]
SMARCAL1	OTTKXLUZ	Strong	Genetic Variation	[134]
SPIB	OTO4YKYI	Strong	Altered Expression	[135]
SUB1	OTK71JYU	Strong	Altered Expression	[114]
TCL1B	OT4CSO39	Strong	Altered Expression	[54]
TET2	OTKKT03T	Strong	Biomarker	[136]
TIGAR	OTR7NMRJ	Strong	Altered Expression	[137]
TMEM132D	OTV6I4Z0	Strong	Biomarker	[138]
ARHGAP24	OTCQCEZS	Definitive	Genetic Variation	[139]
IL2RG	OTRZ3OMY	Definitive	Biomarker	[140]
MAF	OT1GR3IZ	Definitive	Altered Expression	[141]
NOCT	OTVSYP2D	Definitive	Biomarker	[142]
PIAS2	OTJLSC3V	Definitive	Altered Expression	[143]
RPL22	OTVCN8K0	Definitive	Biomarker	[144]
TIA1	OTGPN3P8	Definitive	Biomarker	[145]
------------------------------------------------------------------------------------


⏷ Show the Full List of 90 DOT(s)

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	ClinicalTrials.gov (NCT03902184) IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (TELLOMAK). U.S. National Institutes of Health.
4	ClinicalTrials.gov (NCT03952078) A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma. U.S. National Institutes of Health.
5	ClinicalTrials.gov (NCT04502446) A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM). U.S. National Institutes of Health.
6	The ITM2B (BRI2) gene is a target of BCL6 repression: Implications for lymphomas and neurodegenerative diseases.Biochim Biophys Acta. 2015 May;1852(5):742-8. doi: 10.1016/j.bbadis.2014.12.018. Epub 2014 Dec 31.
7	American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma.Ann Diagn Pathol. 2019 Apr;39:105-110. doi: 10.1016/j.anndiagpath.2019.02.001. Epub 2019 Feb 6.
8	Modulation of the Fas-apoptosis-signalling pathway by functional polymorphisms at Fas, FasL and Fadd and their implication in T-cell lymphoblastic lymphoma susceptibility.Carcinogenesis. 2010 Dec;31(12):2165-71. doi: 10.1093/carcin/bgq201. Epub 2010 Oct 1.
9	Expression of the checkpoint receptors LAG-3, TIM-3 and VISTA in peripheral T cell lymphomas.J Clin Pathol. 2020 Apr;73(4):197-203. doi: 10.1136/jclinpath-2019-206117. Epub 2019 Oct 31.
10	CD20-positive primary nasal peripheral T-cell lymphoma: An analysis of one case and review of the literature.Cytometry B Clin Cytom. 2020 Jul;98(4):348-354. doi: 10.1002/cyto.b.21852. Epub 2019 Nov 4.
11	Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma.Nat Med. 2019 Jan;25(1):130-140. doi: 10.1038/s41591-018-0262-9. Epub 2018 Dec 3.
12	Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability.Clin Cancer Res. 2020 Feb 1;26(3):690-703. doi: 10.1158/1078-0432.CCR-19-1486. Epub 2019 Oct 21.
13	PKC inhibition of sotrastaurin has antitumor activity in diffuse large B-cell lymphoma via regulating the expression of MCT-1.Acta Biochim Biophys Sin (Shanghai). 2018 Apr 1;50(4):399-407. doi: 10.1093/abbs/gmy021.
14	Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma.Blood. 2011 Jan 13;117(2):585-90. doi: 10.1182/blood-2010-07-295097. Epub 2010 Oct 15.
15	Germline genetics of cancer of unknown primary (CUP) and its specific subtypes.Oncotarget. 2016 Apr 19;7(16):22140-9. doi: 10.18632/oncotarget.7903.
16	Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma.Cancer Cell. 2018 Feb 12;33(2):322-336.e8. doi: 10.1016/j.ccell.2018.01.002.
17	Study of L-Asparaginase, Vincristine, and Dexamethasone Combined With Intensity-modulated Radiation Therapy in Early-Stage Nasal NK/T-Cell Lymphoma.Am J Clin Oncol. 2020 Apr;43(4):257-262. doi: 10.1097/COC.0000000000000647.
18	Repression of Ccr9 transcription in mouse T lymphocyte progenitors by the Notch signaling pathway.J Immunol. 2015 Apr 1;194(7):3191-200. doi: 10.4049/jimmunol.1402443. Epub 2015 Feb 20.
19	Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas.Blood. 2018 Oct 4;132(14):1495-1506. doi: 10.1182/blood-2018-04-842708. Epub 2018 Aug 8.
20	Recurrent partial trisomy 1q22-q44 in clonal intraepithelial lymphocytes in refractory celiac sprue.Gastroenterology. 2003 Jul;125(1):40-6. doi: 10.1016/s0016-5085(03)00692-9.
21	NK-/T-cell lymphoma resembling hydroa vacciniforme with positive CD4 marker expression: a diagnostic difficulty.Am J Dermatopathol. 2013 Feb;35(1):94-7. doi: 10.1097/DAD.0b013e3182674895.
22	Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter.Am J Pathol. 2000 Oct;157(4):1137-46. doi: 10.1016/S0002-9440(10)64629-9.
23	Dysregulated choline metabolism in T-cell lymphoma: role of choline kinase- and therapeutic targeting.Blood Cancer J. 2015 Mar 13;5(3):287. doi: 10.1038/bcj.2015.10.
24	The CREB Coactivator CRTC2 Is a Lymphoma Tumor Suppressor that Preserves Genome Integrity through Transcription of DNA Mismatch Repair Genes.Cell Rep. 2015 Jun 9;11(9):1350-7. doi: 10.1016/j.celrep.2015.04.052. Epub 2015 May 21.
25	Germinal-center T-helper-cell markers PD-1 and CXCL13 are both expressed by neoplastic cells in angioimmunoblastic T-cell lymphoma.Am J Clin Pathol. 2009 Jan;131(1):33-41. doi: 10.1309/AJCP62WRKERPXDRT.
26	Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma.Nat Genet. 2015 Sep;47(9):1061-6. doi: 10.1038/ng.3358. Epub 2015 Jul 20.
27	Inhibition of sonic hedgehog signaling blocks cell migration and growth but induces apoptosis via suppression of FOXQ1 in natural killer/T-cell lymphoma.Leuk Res. 2018 Jan;64:1-9. doi: 10.1016/j.leukres.2017.11.001. Epub 2017 Nov 11.
28	Identification of a common clonal human immunodeficiency virus integration site in human immunodeficiency virus-associated lymphomas.Cancer Res. 1994 Apr 15;54(8):2069-72.
29	Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma.Nat Commun. 2019 Sep 16;10(1):4209. doi: 10.1038/s41467-019-12032-9.
30	Nodal CD8 positive cytotoxic T-cell lymphoma: a distinct clinicopathological entity.Mod Pathol. 2002 Nov;15(11):1131-9. doi: 10.1097/01.MP.0000036343.61268.64.
31	Covalent inhibition of histone deacetylase 8 by 3,4-dihydro-2H-pyrimido[1,2-c][1,3]benzothiazin-6-imine.Biochim Biophys Acta Gen Subj. 2019 Mar;1863(3):577-585. doi: 10.1016/j.bbagen.2019.01.001. Epub 2019 Jan 3.
32	Exosomes Isolated from Ascites of T-Cell Lymphoma-Bearing Mice Expressing Surface CD24 and HSP-90 Induce a Tumor-Specific Immune Response.Front Immunol. 2017 Mar 16;8:286. doi: 10.3389/fimmu.2017.00286. eCollection 2017.
33	IL-13 and IL-13R1 are overexpressed in extranodal natural killer/T cell lymphoma and mediate tumor cell proliferation.Biochem Biophys Res Commun. 2018 Sep 18;503(4):2715-2720. doi: 10.1016/j.bbrc.2018.08.030. Epub 2018 Aug 11.
34	Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human.Cancer Res. 2006 Jan 15;66(2):812-9. doi: 10.1158/0008-5472.CAN-05-2154.
35	ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma.Cancer Cell Int. 2019 Feb 14;19:32. doi: 10.1186/s12935-019-0754-9. eCollection 2019.
36	JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia. 2014 Feb;28(2):338-48. doi: 10.1038/leu.2013.157. Epub 2013 May 21.
37	Chromosomal translocation t(11;18)(q21;q21) in gastrointestinal mucosa associated lymphoid tissue lymphoma.J Clin Pathol. 2003 Jan;56(1):36-42. doi: 10.1136/jcp.56.1.36.
38	Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma with KIR3DL2 and NKp46 expression in a human immunodeficiency virus carrier.J Cutan Pathol. 2015 Mar;42(3):199-205. doi: 10.1111/cup.12448. Epub 2014 Dec 23.
39	Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma.J Hematol Oncol. 2019 Jul 24;12(1):80. doi: 10.1186/s13045-019-0768-8.
40	PARP-1/PARP-2 double deficiency in mouse T cells results in faulty immune responses and T lymphomas.Sci Rep. 2017 Feb 9;7:41962. doi: 10.1038/srep41962.
41	Application of Immunophenotyping and Heteroduplex Polymerase Chain Reaction (hPARR) for Diagnosis of Canine Lymphomas.Asian Pac J Cancer Prev. 2016;17(6):2909-16.
42	Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance.Acta Haematol. 2020;143(1):78-88. doi: 10.1159/000500974. Epub 2019 Jul 22.
43	Repression of the PDCD2 gene by BCL6 and the implications for the pathogenesis of human B and T cell lymphomas.Proc Natl Acad Sci U S A. 2007 May 1;104(18):7449-54. doi: 10.1073/pnas.0701770104. Epub 2007 Apr 27.
44	PIM1 overexpression in T-cell lymphomas protects tumor cells from apoptosis and confers doxorubicin resistance by upregulating c-myc expression.Acta Biochim Biophys Sin (Shanghai). 2018 Aug 1;50(8):800-806. doi: 10.1093/abbs/gmy076.
45	Presence of Epstein-Barr virus in extranodal T-cell lymphomas: differences in relation to site.Blood. 1994 Mar 15;83(6):1612-8.
46	Activation of peroxisome proliferator-activated receptor gamma contributes to the survival of T lymphoma cells by affecting cellular metabolism. Am J Pathol. 2007 Feb;170(2):722-32. doi: 10.2353/ajpath.2007.060651.
47	Fusion of MLL and MSF in adult de novo acute myelomonocytic leukemia (M4) with t(11;17)(q23;q25).Int J Hematol. 2002 Jun;75(5):503-7. doi: 10.1007/BF02982114.
48	PKC theta mediates pre-TCR signaling and contributes to Notch3-induced T-cell leukemia.Oncogene. 2005 Feb 3;24(6):992-1000. doi: 10.1038/sj.onc.1208302.
49	Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL.Brain Pathol. 1998 Apr;8(2):263-76. doi: 10.1111/j.1750-3639.1998.tb00152.x.
50	Identification of cell-type-specific mutations in nodal T-cell lymphomas.Blood Cancer J. 2017 Jan 6;7(1):e516. doi: 10.1038/bcj.2016.122.
51	STAT3 Dysregulation in Mature T and NK Cell Lymphomas.Cancers (Basel). 2019 Nov 2;11(11):1711. doi: 10.3390/cancers11111711.
52	EBV lymphoproliferative-associated disease and primary cardiac T-cell lymphoma in a STK4 deficient patient: A case report.Medicine (Baltimore). 2017 Dec;96(48):e8852. doi: 10.1097/MD.0000000000008852.
53	Genomic loss of the putative tumor suppressor gene E2A in human lymphoma.J Exp Med. 2011 Aug 1;208(8):1585-93. doi: 10.1084/jem.20101785. Epub 2011 Jul 25.
54	Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues.Cancer Res. 2000 Apr 15;60(8):2095-100.
55	High Tiam1 expression predicts positive lymphatic metastasis and worse survival in patients with malignant solid tumors: a systematic review and meta-analysis.Onco Targets Ther. 2019 Jul 25;12:5925-5936. doi: 10.2147/OTT.S191571. eCollection 2019.
56	Cessation of autonomous proliferation of mouse lymphoma EL4 by fusion with a T cell line.Int J Cancer. 1990 Mar 15;45(3):540-5. doi: 10.1002/ijc.2910450328.
57	BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders.Hum Pathol. 2005 Oct;36(10):1113-9. doi: 10.1016/j.humpath.2005.08.005.
58	The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily.Int Immunol. 1998 Nov;10(11):1693-702. doi: 10.1093/intimm/10.11.1693.
59	IL-13 Contributes to Drug Resistance of NK/T-Cell Lymphoma Cells by Regulating ABCC4.Biomed Res Int. 2018 Dec 13;2018:2606834. doi: 10.1155/2018/2606834. eCollection 2018.
60	Pharmacological inhibition of carbonic anhydrase XII interferes with cell proliferation and induces cell apoptosis in T-cell lymphomas.Cancer Lett. 2013 Jun 1;333(1):76-88. doi: 10.1016/j.canlet.2013.01.020. Epub 2013 Jan 21.
61	Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.Haematologica. 2018 Jan;103(1):126-135. doi: 10.3324/haematol.2017.177279. Epub 2017 Oct 12.
62	Nasal T-cell lymphoma causally associated with Epstein-Barr virus: clinicopathologic, phenotypic, and genotypic studies.Cancer. 1996 May 15;77(10):2137-49. doi: 10.1002/(SICI)1097-0142(19960515)77:10<2137::AID-CNCR27>3.0.CO;2-V.
63	The helix-loop-helix protein Id2 is expressed differentially and induced by myc in T-cell lymphomas.Cancer. 2008 Feb 1;112(3):552-61. doi: 10.1002/cncr.23196.
64	IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.Lancet Oncol. 2019 Aug;20(8):1160-1170. doi: 10.1016/S1470-2045(19)30320-1. Epub 2019 Jun 25.
65	MUC1 (CD227) interacts with lck tyrosine kinase in Jurkat lymphoma cells and normal T cells.J Leukoc Biol. 2005 Jan;77(1):90-9. doi: 10.1189/jlb.0604333. Epub 2004 Oct 28.
66	Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis.J Vet Sci. 2001 Dec;2(3):167-79.
67	Expression of the Tpl2/Cot oncogene in human T-cell neoplasias.Mol Cancer. 2004 Dec 3;3(1):34. doi: 10.1186/1476-4598-3-34.
68	Oncogenes, tumor suppressors and p52 NF-kappaB.Oncogene. 2003 Oct 23;22(48):7553-6. doi: 10.1038/sj.onc.1207139.
69	Genetic screening for synthetic lethal partners of polynucleotide kinase/phosphatase: potential for targeting SHP-1-depleted cancers.Cancer Res. 2012 Nov 15;72(22):5934-44. doi: 10.1158/0008-5472.CAN-12-0939. Epub 2012 Sep 7.
70	The aberrant activation of Wnt pathway caused by -catenin mutation and its prognostic significance in NK/T-cell lymphoma.Neoplasma. 2019 Jan 15;66(1):20-27. doi: 10.4149/neo_2018_170929N619. Epub 2018 Aug 9.
71	Characteristics of TCR, ZAP-70, and FcRI gene expression in patients with T- and NK/T-cell lymphoma.DNA Cell Biol. 2015 Mar;34(3):201-7. doi: 10.1089/dna.2014.2693. Epub 2014 Dec 16.
72	Asparagine synthetase expression is associated with the sensitivity to asparaginase in extranodal natural killer/T-cell lymphoma in vivo and in vitro.Onco Targets Ther. 2018 Oct 8;11:6605-6615. doi: 10.2147/OTT.S155930. eCollection 2018.
73	Evolving Strategies for the Treatment of T-Cell Lymphoma: A Systematic Review and Recent Patents.Recent Pat Anticancer Drug Discov. 2018;13(3):308-340. doi: 10.2174/1574892813666180517102801.
74	Growth factor independent 1B (Gfi1b) is an E2A target gene that modulates Gata3 in T-cell lymphomas.Blood. 2007 May 15;109(10):4406-14. doi: 10.1182/blood-2006-08-043331. Epub 2007 Feb 1.
75	Immunophenotyping and gene rearrangement analysis provide additional criteria to differentiate between cutaneous T-cell lymphomas and pseudo-T-cell lymphomas.Am J Pathol. 1997 Jun;150(6):1941-9.
76	No evidence for deletions of the NBS1 gene in lymphomas.Cancer Genet Cytogenet. 2001 Apr 1;126(1):60-2. doi: 10.1016/s0165-4608(00)00390-3.
77	PCDH10 promoter hypermethylation is frequent in most histologic subtypes of mature lymphoid malignancies and occurs early in lymphomagenesis.Genes Chromosomes Cancer. 2013 Nov;52(11):1030-41. doi: 10.1002/gcc.22098. Epub 2013 Aug 9.
78	Primary cutaneous non-Hodgkin lymphoma: results of a retrospective analysis in the light of the recent ILROG guidelines.Tumori. 2018 Oct;104(5):394-400. doi: 10.5301/tj.5000606. Epub 2018 May 8.
79	Granulysin, a novel marker for extranodal NK/T cell lymphoma, nasal type.Virchows Arch. 2018 Dec;473(6):749-757. doi: 10.1007/s00428-018-2434-x. Epub 2018 Aug 27.
80	Expression of S100 Protein in CD4-positive T-cell Lymphomas Is Often Associated With T-cell Prolymphocytic Leukemia.Am J Surg Pathol. 2015 Dec;39(12):1679-87. doi: 10.1097/PAS.0000000000000496.
81	Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.Oncotarget. 2016 Nov 22;7(47):76793-76805. doi: 10.18632/oncotarget.12529.
82	Enhanced Notch activation is advantageous but not essential for T cell lymphomagenesis in Id1 transgenic mice.PLoS One. 2012;7(2):e32944. doi: 10.1371/journal.pone.0032944. Epub 2012 Feb 29.
83	Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma.Am J Surg Pathol. 2012 May;36(5):716-25. doi: 10.1097/PAS.0b013e3182487158.
84	Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection.Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15036-41. doi: 10.1073/pnas.232381299. Epub 2002 Oct 30.
85	Cyclophosphamide enhances the release of tumor exosomes that elicit a specific immune response in vivo in a murine T-cell lymphoma.Vaccine. 2019 Mar 14;37(12):1565-1576. doi: 10.1016/j.vaccine.2019.02.004. Epub 2019 Feb 15.
86	Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type.Cancer Res Treat. 2018 Jul;50(3):670-680. doi: 10.4143/crt.2017.051. Epub 2017 Jul 3.
87	Fusion of the genes ataxin 2 like, ATXN2L, and Janus kinase 2, JAK2, in cutaneous CD4 positive T-cell lymphoma.Oncotarget. 2017 Oct 10;8(61):103775-103784. doi: 10.18632/oncotarget.21790. eCollection 2017 Nov 28.
88	Comprehensive cytogenetic study of primary cutaneous gamma-delta T-cell lymphoma by means of spectral karyotyping and genome-wide single nucleotide polymorphism array.Cancer Genet. 2012 Sep;205(9):459-64. doi: 10.1016/j.cancergen.2012.05.006. Epub 2012 Jul 21.
89	Expression and clinical significance of centrosomal protein 55 in T-cell lymphoma.J Cancer Res Ther. 2018 Jan;14(1):94-98. doi: 10.4103/jcrt.JCRT_758_17.
90	Mutation of inhibitory helix-loop-helix protein Id3 causes T-cell lymphoma in mice.Blood. 2010 Dec 16;116(25):5615-21. doi: 10.1182/blood-2010-03-274506. Epub 2010 Sep 17.
91	IL13-Mediated Dectin-1 and Mannose Receptor Overexpression Promotes Macrophage Antitumor Activities through Recognition of Sialylated Tumor Cells.Cancer Immunol Res. 2019 Feb;7(2):321-334. doi: 10.1158/2326-6066.CIR-18-0213. Epub 2019 Jan 4.
92	In vivo interference with Skp1 function leads to genetic instability and neoplastic transformation.Mol Cell Biol. 2002 Dec;22(23):8375-87. doi: 10.1128/MCB.22.23.8375-8387.2002.
93	Characterization of two novel cell lines, DERL-2 (CD56+/CD3+/Tcry5+) and DERL-7 (CD56+/CD3-/TCRgammadelta-), derived from a single patient with CD56+ non-Hodgkin's lymphoma.Leukemia. 2001 Oct;15(10):1641-9. doi: 10.1038/sj.leu.2402239.
94	Epigenetic silencing of the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomas.J Transl Med. 2012 Oct 11;10:209. doi: 10.1186/1479-5876-10-209.
95	The homeoprotein Dlx5 drives murine T-cell lymphomagenesis by directly transactivating Notch and upregulating Akt signaling.Oncotarget. 2017 Feb 28;8(9):14941-14956. doi: 10.18632/oncotarget.14784.
96	A novel recurrent chromosomal inversion implicates the homeobox gene Dlx5 in T-cell lymphomas from Lck-Akt2 transgenic mice.Cancer Res. 2008 Mar 1;68(5):1296-302. doi: 10.1158/0008-5472.CAN-07-3218.
97	Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma.Nat Med. 2018 Feb;24(2):154-164. doi: 10.1038/nm.4456. Epub 2018 Jan 1.
98	Expression of endomucin, a novel endothelial sialomucin, in normal and diseased human skin.J Invest Dermatol. 2002 Dec;119(6):1388-93. doi: 10.1046/j.1523-1747.2002.19647.x.
99	Frequent concomitant epigenetic silencing of the stress-responsive tumor suppressor gene CADM1, and its interacting partner DAL-1 in nasal NK/T-cell lymphoma.Int J Cancer. 2009 Apr 1;124(7):1572-8. doi: 10.1002/ijc.24123.
100	Separase loss of function cooperates with the loss of p53 in the initiation and progression of T- and B-cell lymphoma, leukemia and aneuploidy in mice.PLoS One. 2011;6(7):e22167. doi: 10.1371/journal.pone.0022167. Epub 2011 Jul 25.
101	Expression of Fbxo7 in haematopoietic progenitor cells cooperates with p53 loss to promote lymphomagenesis.PLoS One. 2011;6(6):e21165. doi: 10.1371/journal.pone.0021165. Epub 2011 Jun 17.
102	Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.Leukemia. 2007 Jun;21(6):1183-8. doi: 10.1038/sj.leu.2404662. Epub 2007 Mar 22.
103	Epigenetic silencing of miR-490-3p promotes development of an aggressive colorectal cancer phenotype through activation of the Wnt/-catenin signaling pathway.Cancer Lett. 2016 Jun 28;376(1):178-87. doi: 10.1016/j.canlet.2016.03.024. Epub 2016 Mar 29.
104	Expression and chromosomal localization of the gene for the human transcriptional repressor GCF.J Biol Chem. 1992 Jan 25;267(3):1689-94.
105	Deregulated expression of NKL homeobox genes in T-cell lymphomas.Oncotarget. 2019 May 14;10(35):3227-3247. doi: 10.18632/oncotarget.26929. eCollection 2019 May 14.
106	NK/T-cell lymphoma associated with Epstein-Barr virus in a patient infected with human immunodeficiency virus: an autopsy case.Int J Hematol. 2004 Jun;79(5):480-3. doi: 10.1532/ijh97.a10316.
107	The serine protease granzyme M is preferentially expressed in NK-cell, gamma delta T-cell, and intestinal T-cell lymphomas: evidence of origin from lymphocytes involved in innate immunity.Blood. 2003 May 1;101(9):3590-3. doi: 10.1182/blood-2002-09-2908. Epub 2002 Dec 27.
108	Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia.Anticancer Drugs. 2019 Feb;30(2):117-127. doi: 10.1097/CAD.0000000000000696.
109	CD56/neural cell adhesion molecule expression in primary extranodal Ki-1/CD30+ lymphoma. Report of a pediatric case with simultaneous cutaneous and bone localizations.Am J Dermatopathol. 1997 Aug;19(4):384-90. doi: 10.1097/00000372-199708000-00011.
110	Members of a family of JmjC domain-containing oncoproteins immortalize embryonic fibroblasts via a JmjC domain-dependent process.Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1907-12. doi: 10.1073/pnas.0711865105. Epub 2008 Feb 4.
111	A Survey of Somatic Mutations in 41 Genes in a Cohort of T-Cell Lymphomas Identifies Frequent Mutations in Genes Involved in Epigenetic Modification.Appl Immunohistochem Mol Morphol. 2019 Jul;27(6):416-422. doi: 10.1097/PAI.0000000000000644.
112	LMO4 Is a Disease-Provocative Transcription Coregulator Activated by IL-23 in Psoriatic Keratinocytes.J Invest Dermatol. 2018 May;138(5):1078-1087. doi: 10.1016/j.jid.2017.12.010. Epub 2017 Dec 16.
113	Occult recurrence of monomorphic epitheliotropic intestinal T-cell lymphoma and the role of MATK gene expression in diagnosis.Hematol Oncol. 2017 Dec;35(4):852-855. doi: 10.1002/hon.2288. Epub 2016 Mar 7.
114	Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas.Blood. 1999 Sep 1;94(5):1773-81.
115	The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK?T-cell lymphoma.Mol Cancer. 2015 Feb 25;14:53. doi: 10.1186/s12943-015-0324-2.
116	Clinicopathological characterization and genomic aberrations in subcutaneous panniculitis-like T-cell lymphoma.J Invest Dermatol. 2008 Sep;128(9):2304-9. doi: 10.1038/jid.2008.6. Epub 2008 Mar 13.
117	Novel IGH and MYC Translocation Partners in Diffuse Large B-Cell Lymphomas.Genes Chromosomes Cancer. 2016 Dec;55(12):932-943. doi: 10.1002/gcc.22391. Epub 2016 Jul 12.
118	Disruption of TCBA1 associated with a de novo t(1;6)(q32.2;q22.3) presenting in a child with developmental delay and recurrent infections.J Med Genet. 2006 Feb;43(2):143-7. doi: 10.1136/jmg.2004.029660. Epub 2005 May 20.
119	The use of flow cytometry in the diagnosis and biological characterization of the non-Hodgkin's lymphomas.Ann N Y Acad Sci. 1986;468:171-7. doi: 10.1111/j.1749-6632.1986.tb42038.x.
120	PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity.BMC Cancer. 2018 Sep 21;18(1):910. doi: 10.1186/s12885-018-4782-y.
121	A neutralized human LMP1-IgG inhibits ENKTL growth by suppressing the JAK3/STAT3 signaling pathway.Oncotarget. 2017 Feb 14;8(7):10954-10965. doi: 10.18632/oncotarget.14032.
122	T-cell acute lymphoblastic leukemia in association with Brjeson-Forssman-Lehmann syndrome due to a mutation in PHF6.Pediatr Blood Cancer. 2010 Oct;55(4):722-4. doi: 10.1002/pbc.22574.
123	Overexpression of p101 activates PI3Kgamma signaling in T cells and contributes to cell survival.Oncogene. 2007 Oct 25;26(49):7049-57. doi: 10.1038/sj.onc.1210504. Epub 2007 May 7.
124	Association of the long non-coding RNA MALAT1 with the polycomb repressive complex pathway in T and NK cell lymphoma.Oncotarget. 2017 May 9;8(19):31305-31317. doi: 10.18632/oncotarget.15453.
125	Receptor-type tyrosine-protein phosphatase directly targets STAT3 activation for tumor suppression in nasal NK/T-cell lymphoma.Blood. 2015 Mar 5;125(10):1589-600. doi: 10.1182/blood-2014-07-588970. Epub 2015 Jan 22.
126	MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies.Leukemia. 2000 Mar;14(3):449-56. doi: 10.1038/sj.leu.2401696.
127	The use of knockout mice reveals a synergistic role of the Vav1 and Rasgrf2 gene deficiencies in lymphomagenesis and metastasis.PLoS One. 2009 Dec 14;4(12):e8229. doi: 10.1371/journal.pone.0008229.
128	Deregulated expression of RasGRP1 initiates thymic lymphomagenesis independently of T-cell receptors.Oncogene. 2005 Apr 14;24(16):2695-704. doi: 10.1038/sj.onc.1208334.
129	A patient with Baller-Gerold syndrome and midline NK/T lymphoma.Am J Med Genet A. 2009 Feb 15;149A(4):755-9. doi: 10.1002/ajmg.a.32736.
130	Immunophenotypic Shifts in Primary Cutaneous T-Cell Lymphoma Suggest Antigenic Modulation: A Study of Sequential Biopsy Specimens.Am J Surg Pathol. 2017 Apr;41(4):431-445. doi: 10.1097/PAS.0000000000000786.
131	PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis.Nature. 2017 Dec 7;552(7683):121-125. doi: 10.1038/nature24649. Epub 2017 Nov 15.
132	The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype.Medicine (Baltimore). 2014 Oct;93(17):255-266. doi: 10.1097/MD.0000000000000088.
133	Suppressor mutations within the core binding factor (CBF/AML1) binding site of a T-cell lymphomagenic retrovirus.J Virol. 1999 Mar;73(3):2143-52. doi: 10.1128/JVI.73.3.2143-2152.1999.
134	Defective replication stress response inhibits lymphomagenesis and impairs lymphocyte reconstitution.Oncogene. 2017 May 4;36(18):2553-2564. doi: 10.1038/onc.2016.408. Epub 2016 Oct 31.
135	SPIB, a novel immunohistochemical marker for human blastic plasmacytoid dendritic cell neoplasms: characterization of its expression in major hematolymphoid neoplasms.Blood. 2013 Jan 24;121(4):643-7. doi: 10.1182/blood-2012-08-447599. Epub 2012 Nov 19.
136	Paradoxical association of TET loss of function with genome-wide DNA hypomethylation.Proc Natl Acad Sci U S A. 2019 Aug 20;116(34):16933-16942. doi: 10.1073/pnas.1903059116. Epub 2019 Aug 1.
137	The TP53-Induced Glycolysis and Apoptosis Regulator mediates cooperation between HTLV-1 p30(II) and the retroviral oncoproteins Tax and HBZ and is highly expressed in an in vivo xenograft model of HTLV-1-induced lymphoma.Virology. 2018 Jul;520:39-58. doi: 10.1016/j.virol.2018.05.007. Epub 2018 May 26.
138	Leptin and its receptor in glucose metabolism of T-cell lymphoma.Oncol Lett. 2018 Nov;16(5):5838-5846. doi: 10.3892/ol.2018.9356. Epub 2018 Aug 23.
139	Frequent inactivation of the p73 gene by abnormal methylation or LOH in non-Hodgkin's lymphomas.Int J Cancer. 2002 Nov 1;102(1):15-9. doi: 10.1002/ijc.10618.
140	Gene therapy: therapeutic gene causing lymphoma.Nature. 2006 Apr 27;440(7088):1123. doi: 10.1038/4401123a.
141	c-Maf expression in angioimmunoblastic T-cell lymphoma.Am J Surg Pathol. 2007 Nov;31(11):1695-702. doi: 10.1097/PAS.0b013e318054dbcf.
142	Molecular etiology of mature T-cell non-Hodgkin's lymphomas.Front Biosci. 2003 Jan 1;8:d156-75. doi: 10.2741/922.
143	The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance.Genes Dev. 2010 Jun 15;24(12):1281-94. doi: 10.1101/gad.585710.
144	Ribosomal Protein Rpl22 Controls the Dissemination of T-cell Lymphoma.Cancer Res. 2016 Jun 1;76(11):3387-96. doi: 10.1158/0008-5472.CAN-15-2698. Epub 2016 Apr 5.
145	Classification of cell lineage and anatomical site, and prognosis of extranodal T-cell lymphoma -- natural killer cell, cytotoxic T lymphocyte, and non-NK/CTL types.Virchows Arch. 2002 Apr;440(4):425-35. doi: 10.1007/s00428-001-0545-1. Epub 2001 Dec 6.